Basic Research for Diagnostics and Surveillance in Lower Resource Environments
低资源环境诊断和监测基础研究
基本信息
- 批准号:10669039
- 负责人:
- 金额:$ 67.11万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2021
- 资助国家:美国
- 起止时间:2021-08-12 至 2025-07-31
- 项目状态:未结题
- 来源:
- 关键词:2019-nCoVAnimalsBasic ScienceBiological AssayBusinessesCOVID detectionCessation of lifeChemistryClinicalCommunitiesComputer softwareDNADataDemocracyDemographyDiagnosticDiagnostic Reagent KitsDiagnostics ResearchDiseaseDropoutDropsEmergency SituationEnzymatic BiochemistryEnzymesEpidemicExperimental DesignsFailureFoundationsFutureGuidelinesHumanInformation SystemsKnowledgeLearningMalaiseManufacturerMedicareMissionMolecular DiagnosisMolecular EvolutionNational Institute of Allergy and Infectious DiseaseNucleic AcidsOralPaperPathogen detectionPatientsPhysiciansProcessRNARectumRegulationReproducibilityResearchResearch PersonnelResistanceResource-limited settingResourcesSamplingScienceSpecific qualifier valueSpeedSymptomsSystemTemperatureTestingThermodynamicsTimeTravelVaginaWritingcare costscostdeep sequencingdesigneconomic impactemerging pathogenexperimental studyflexibilitygenetic informationimprovedinnovationmanufacturemeetingsmeltingmolecular recognitionnew technologypandemic diseasepathogenpreventrectalrelative costresponserestraintstatistics
项目摘要
Basic Research to Diagnostics and Surveillance in Lower Resource Environments
Foundation for Applied Molecular Evolution
Steven A. Benner
ABSTRACT
We will deliver to the NIAID and CDC communities, through basic research, a scientific understanding of
pairing, mispairing, and enzymology of natural DNA and RNA (collectively xNA) that goes deeper than the
axiom that "A pairs with T, and G pairs with C". The experiments are designed to learn:
(a) Why robust multiplexed PCR (mPCR) for clinical use seems impossible with more than 20-30 targets.
(b) Why conventional expedients (including careful primer and probe design, internal nesting, and external
tagging) fail to robustly support multiplexing beyond ~30 targets.
(c) Why those failures are not reproducible from sample to sample.
(d) Why conventional multiplexes targeting n targets often collapse when an n+1th target is added. This
prevents, when a new pathogen emerges (as for 2019-nCoV), a diagnostics maker from simply adding a new
target to an existing mPCR kit, thereby meeting the emergency need.
(e) Why manufacturing specs become increasingly more demanding as the level of multiplexing increases.
These problems restrain 21st century diagnostics to two 20th century design and regulatory paradigms.
(i) A "guess-then-test" paradigm for singleplexed molecular diagnosis, which requires physician to guess
which pathogen might be associated with patient malaise, prescribe a ~$150 singleplexed test based on that
guess, and re-prescribe further tests until a guess proves correct.
(ii) The "inflexible-multiplexed-panel" paradigm. Here, assays are bundled into a multiplex appropriate for a
specific sample and symptom set; failure (d) prevents that multiplex from changing for emerging diseases.
By developing the science of both natural and unnatural DNA (including artificially expanded genetic
information systems, AEGIS, and self avoiding molecular recognition systems, SAMRS), this project will deliver
to researchers, manufacturers, and the FDA science to meet the 21st century NIAID mission. We will:
Task 1. Complete thermodynamic and enzyme rules to place SAMRS optimally in primers that target both DNA
and RNA. Rules will be metricked by comparing predictions made with these rules to experiments.
Task 2. Metric, by deep sequencing, mPCR failures (a) through (e).
Task 3. Metric how AEGIS and SAMRS mitigate or eliminate failures (a) through (e).
Task 4. Identify failure modes that arise with RNA targets specifically. Since RNA has folding options not
available to DNA, these modes may be especially resistant to nucleic acid innovations.
Task 5. Build a body of statistical knowledge for AEGIS-SAMRS mPCR, especially with respect to "add-ons",
quantitative amplification, and manufacturing tolerances. This will help move away from "guess-then-
test" and "inflexible-multiplexed-panel" paradigms, lowing cost, supporting FDA regulatory processes,
and better managing pandemics.
1
浅层资源环境诊断与监测的基础研究
应用分子进化基础
史蒂文·A·本纳
摘要
我们将通过基础研究向NIAID和CDC社区提供对
天然DNA和RNA(统称为XNA)的配对、错配和酶学
公理“A与T配对,G与C配对”。这些实验旨在了解:
(A)为什么在超过20-30个靶点的情况下,稳健的多重聚合酶链式反应(MPCR)似乎不可能用于临床。
(B)为什么采用传统的权宜之计(包括仔细的引子和探针设计、内部嵌套和外部嵌套
标记)无法有力地支持超过约30个目标的多路传输。
(C)为什么这些不合格不能在不同的样本中重现。
(D)为什么当增加第n+1个目标时,以n个目标为目标的传统多路复用器经常崩溃。这
当出现新的病原体(如2019-nCoV)时,防止诊断人员简单地添加新的
以现有的mPCR试剂盒为目标,从而满足紧急需要。
(E)为什么随着多路复用水平的提高,制造规格变得越来越苛刻。
这些问题将21世纪的诊断学局限于20世纪的两种设计和监管范式。
(I)单链分子诊断的“先猜后测”模式,这需要医生猜测
哪种病原体可能与患者不适有关,根据这一点,开出一项约150美元的单基因测试
猜测,并重新开出进一步测试的处方,直到猜测被证明是正确的。
(2)“僵化--多路--小组”模式。在这里,分析被捆绑到适合于
特定样本和症状集;失败(D)防止该多重物因新出现的疾病而改变。
通过发展天然和非天然DNA的科学(包括人工扩增的基因
信息系统、宙斯盾和自我避免分子识别系统(SAMRS),该项目将提供
对研究人员、制造商和FDA的科学来说,以满足21世纪NIAID的使命。我们会:
任务1.完成热力学规则和酶规则,以便将SAMRS最佳地放置在针对两个DNA的引物中
和RNA。规则将通过将使用这些规则做出的预测与实验进行比较来衡量。
任务2.通过深度测序来衡量mPCR故障(A)至(E)。
任务3.衡量Aegis和SAMRS如何减轻或消除故障(A)至(E)。
任务4.明确RNA靶标出现的失败模式。由于RNA具有折叠选项而不是
这些模式可用于DNA,可能尤其对核酸创新具有抵抗性。
任务5.建立宙斯盾-SAMRS mPCR统计知识体系,特别是关于“附加项目”,
定量放大和制造公差。这将有助于摆脱“猜想-然后-
测试“和”不灵活的多路复用板“范例,降低成本,支持FDA的监管程序,
以及更好地管理流行病。
1
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
STEVEN A BENNER其他文献
STEVEN A BENNER的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('STEVEN A BENNER', 18)}}的其他基金
Easily Used Kits to Evolve Reagents that Covalently Tag and Inactivate Proteins
易于使用的试剂盒可进化出共价标记和灭活蛋白质的试剂
- 批准号:
10626917 - 财政年份:2021
- 资助金额:
$ 67.11万 - 项目类别:
Basic Research for Diagnostics and Surveillance in Lower Resource Environments
低资源环境诊断和监测基础研究
- 批准号:
10468606 - 财政年份:2021
- 资助金额:
$ 67.11万 - 项目类别:
Easily Used Kits to Evolve Reagents that Covalently Tag and Inactivate Proteins
易于使用的试剂盒可进化出共价标记和灭活蛋白质的试剂
- 批准号:
10478279 - 财政年份:2021
- 资助金额:
$ 67.11万 - 项目类别:
Easily Used Kits to Evolve Reagents that Covalently Tag and Inactivate Proteins
易于使用的试剂盒可进化出共价标记和灭活蛋白质的试剂
- 批准号:
10298982 - 财政年份:2021
- 资助金额:
$ 67.11万 - 项目类别:
Equipment Supplement to 1R01GM141391-01A1 (Easily Used Kits to Evolve Reagents that Covalently Tag and Inactivate Proteins)
1R01GM141391-01A1 的设备补充(易于使用的试剂盒,用于进化共价标记和灭活蛋白质的试剂)
- 批准号:
10580301 - 财政年份:2021
- 资助金额:
$ 67.11万 - 项目类别:
PHS2019-02 Omnibus Solic of the NIH, CDC, and FDA for SBIR Apps No Clinical Trial (Parent SBIR R43/4
PHS2019-02 NIH、CDC 和 FDA 的 SBIR 应用程序综合 Solic 尚未进行临床试验(母公司 SBIR R43/4
- 批准号:
10476977 - 财政年份:2021
- 资助金额:
$ 67.11万 - 项目类别:
Reagents to Chemically Tag Specific Coronavirus Spike Proteins
化学标记特定冠状病毒刺突蛋白的试剂
- 批准号:
10259048 - 财政年份:2021
- 资助金额:
$ 67.11万 - 项目类别:
相似海外基金
The earliest exploration of land by animals: from trace fossils to numerical analyses
动物对陆地的最早探索:从痕迹化石到数值分析
- 批准号:
EP/Z000920/1 - 财政年份:2025
- 资助金额:
$ 67.11万 - 项目类别:
Fellowship
Animals and geopolitics in South Asian borderlands
南亚边境地区的动物和地缘政治
- 批准号:
FT230100276 - 财政年份:2024
- 资助金额:
$ 67.11万 - 项目类别:
ARC Future Fellowships
The function of the RNA methylome in animals
RNA甲基化组在动物中的功能
- 批准号:
MR/X024261/1 - 财政年份:2024
- 资助金额:
$ 67.11万 - 项目类别:
Fellowship
Ecological and phylogenomic insights into infectious diseases in animals
对动物传染病的生态学和系统发育学见解
- 批准号:
DE240100388 - 财政年份:2024
- 资助金额:
$ 67.11万 - 项目类别:
Discovery Early Career Researcher Award
Zootropolis: Multi-species archaeological, ecological and historical approaches to animals in Medieval urban Scotland
Zootropolis:苏格兰中世纪城市动物的多物种考古、生态和历史方法
- 批准号:
2889694 - 财政年份:2023
- 资助金额:
$ 67.11万 - 项目类别:
Studentship
Using novel modelling approaches to investigate the evolution of symmetry in early animals.
使用新颖的建模方法来研究早期动物的对称性进化。
- 批准号:
2842926 - 财政年份:2023
- 资助金额:
$ 67.11万 - 项目类别:
Studentship
Study of human late fetal lung tissue and 3D in vitro organoids to replace and reduce animals in lung developmental research
研究人类晚期胎儿肺组织和 3D 体外类器官在肺发育研究中替代和减少动物
- 批准号:
NC/X001644/1 - 财政年份:2023
- 资助金额:
$ 67.11万 - 项目类别:
Training Grant
RUI: Unilateral Lasing in Underwater Animals
RUI:水下动物的单侧激光攻击
- 批准号:
2337595 - 财政年份:2023
- 资助金额:
$ 67.11万 - 项目类别:
Continuing Grant
RUI:OSIB:The effects of high disease risk on uninfected animals
RUI:OSIB:高疾病风险对未感染动物的影响
- 批准号:
2232190 - 财政年份:2023
- 资助金额:
$ 67.11万 - 项目类别:
Continuing Grant
A method for identifying taxonomy of plants and animals in metagenomic samples
一种识别宏基因组样本中植物和动物分类的方法
- 批准号:
23K17514 - 财政年份:2023
- 资助金额:
$ 67.11万 - 项目类别:
Grant-in-Aid for Challenging Research (Exploratory)